Please note: The information displayed on this page might be outdated.
Scribe Therapeutics: Scribe Therapeutics is a molecular engineering company focused on building best-in-class in vivo therapies to permanently treat the underlying cause of disease. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company is backed by leading individual and institutional investors including Andreessen Horowitz. To learn more about Scribe’s mission to rewrite the story of disease, visit http://www.scribetx.com
North America, US - Pacific
Central Nervous System, Hematology, Immuno-Oncology, Rare Disease
1150 Marina Village Parkway
Alameda, CA 94501
Alameda, CA 94501
Company Participants at Winter Private Company Showcase
Benjamin Oakes, PhD
Scribe Therapeutics, Co-Founder, President & CEO
Benjamin L. Oakes is the co-founder, President, and Chief Executive Officer at Scribe Therapeutics. Previously, as an Innovative Genomics Institute Entrepreneurial Fellow, Ben focused on the holistic engineering of genome editing technologies to build novel genome editing molecules. Ben has contributed to over 25 publications and patent applications on topics including synthetic biology, molecular engineering, CRISPR and zinc finger-based genetic modification. Ben received a Ph.D. in Molecular and Cellular Biology from UC Berkeley in 2017, where he worked in the Doudna Lab and Savage Lab developing CRISPR-Cas9 molecules with enhanced characteristics. Two such projects resulted in distinct versions of synthetic sensing systems that can modify nucleic acids only when triggered by external stimuli, and have found use in both research and pragmatically applied technologies. Prior to his Ph.D. Ben received his B.A. in the fields of Philosophy and Neurobiology and worked as a researcher applying unbiased, combinatorial evolution methods to build tens of thousands of “version one” genome editing tools, providing an open source framework for scientists and medical professionals to modify the genome B.C. — before the discovery of CRISPR technology.
Svetlana Lucas, PhD
Scribe Therapeutics, CBO
Svetlana Lucas is the Chief Business Officer at Scribe Therapeutics, bringing nearly 20 years of experience in strategy, commercialization, and business development leadership to the role. Previously, she served as Senior Vice President, Business Development at Tizona Therapeutics, Inc. (Tizona), a clinical stage immunotherapy company, where she was responsible for the company’s business development strategy and transactions, including global strategic collaboration with AbbVie Inc. Before joining Tizona, Svetlana was Head of Oncology and Inflammation External R&D Team at Amgen Inc. (Amgen), where she oversaw business development activities, including Amgen’s strategic cancer immunotherapy research collaboration and licensing agreement with Kite Pharma, and collaborated with Amgen Ventures on several investments in oncology and inflammation. Svetlana joined Amgen following the acquisition of Onyx Pharmaceuticals, Inc. (Onyx), where she spearheaded the company’s oncology partnering strategy and due diligence of new opportunities. She has held positions of increasing responsibility in strategy, business development, and strategic marketing at Amgen, PDL BioPharma/Facet Biotech (acquired by AbbVie), and XOMA Corporation. Svetlana began her career as a strategy consultant in the Life Sciences practice of McKinsey & Company, Inc. She received her undergraduate degree in Biology from Moscow State University, and her Ph.D. in Molecular Biology and Biochemistry from the California Institute of Technology.